Quest Diagnostics

SPECIMEN INFORMATION

SPECIMEN: ST928414B
REQUISITION: 36962727

Lab ref no:

COLLECTED: 2018/09/27 09:05

RECEIVED: 2018/09/27 09:06 REPORTED: 2018/10/01 18:13 PATIENT INFORMATION

Stock, Kevin

DOB: April 27, 1987

AGE: 31
GENDER: Male
FASTING: Unknown

Clinical Info:

REPORT STATUS: FINAL

ORDERING PHYSICIAN

Hood, Diane
CLIENT INFORMATION

2018-10-01 18:13:00 -0700

DirectLabs

4040 Florida St.

Ste 101

Mandeville, LA 70448

REPORTED: 2018/10/01 18:13			Mandeville, LA 70448	
Test Name	Result	Flag	Reference Range	Lab
FASTING: YES				
FASTING: YES				
LIPID PANEL, STANDARD				
CHOLESTEROL, TOTAL	313	HIGH	<200 mg/dL	01
HDL CHOLESTEROL	111	NORMAL	>40 mg/dL	01
TRIGLYCERIDES	72	NORMAL	<150 mg/dL	01
LDL-CHOLESTEROL	185	HIGH	mg/dL (calc)	01
Reference range: <100				
Desirable range <100 mg/dL for <70 mg/dL for patients with ( with > or = 2 CHD risk factor	CHD or diabetic p			
LDL-C is now calculated using calculation, which is a valid better accuracy than the Fridestimation of LDL-C. Martin SS et al. JAMA. 2013;	dated novel metho edewald equation 310(19): 2061-206	d providing in the 8		
(http://education.QuestDiagno	ostics.com/faq/FA	Q164)		
CHOL/HDLC RATIO	2.8	NORMAL	<5.0 (calc)	01
NON HDL CHOLESTEROL	202	HIGH	<130 mg/dL (calc)	01
For patients with diabetes particle factor, treating to a non-HDI (LDL-C of <70 mg/dL) is constructed option.	L-C goal of <100	mg/dL		
GGT				
GGT	11	NORMAL	3-90 U/L	01
IRON, TOTAL				
IRON, TOTAL	92	NORMAL	50-180 mcg/dL	01
LD				
LD	128	NORMAL	100-220 U/L	01
PHOSPHATE (AS PHOSPHORUS)				
PHOSPHATE (AS PHOSPHORUS)	4.2	NORMAL	2.5-4.5 mg/dL	01
URIC ACID				
URIC ACID	6.7	NORMAL	4.0-8.0 mg/dL	01
Therapeutic target for gout p	patients: <6.0 mg	/dL		
COMPREHENSIVE METABOLIC PANEL				
GLUCOSE	89	NORMAL	65-99 mg/dL	01
Fasting reference interval				
UREA NITROGEN (BUN)	32	HIGH	7-25 mg/dL	01
CREATININE	1.01	NORMAL	0.60-1.35 mg/dL	01
eGFR NON-AFR. AMERICAN	99	NORMAL	> OR = 60	01
			mL/min/1.73m2	
eGFR AFRICAN AMERICAN	114	NORMAL	> OR = 60 mL/min/1.73m2	01
BUN/CREATININE RATIO	32	HIGH	6-22 (calc)	01
SODIUM	140	NORMAL	135-146 mmol/L	01
POTASSIUM	4.8	NORMAL	3.5-5.3 mmol/L	01
CHLORIDE	103	NORMAL	98-110 mmol/L	01
CARBON DIOXIDE	30	NORMAL	20-32 mmol/L	01
			·	

CALCIUM	10.0	NORMAL	8.6-10.3 mg/dL	01
PROTEIN, TOTAL	7.5	NORMAL	6.1-8.1 g/dL	01
ALBUMIN	4.7	NORMAL	3.6-5.1 g/dL	01
GLOBULIN	2.8	NORMAL	1.9-3.7 g/dL (calc)	01
ALBUMIN/GLOBULIN RATIO	1.7	NORMAL	1.0-2.5 (calc)	01
BILIRUBIN, TOTAL	1.2	NORMAL	0.2-1.2 mg/dL	01
ALKALINE PHOSPHATASE	90	NORMAL	40-115 U/L	01
AST	21	NORMAL	10-40 U/L	01
ALT	54	HIGH	9-46 U/L	01
CBC (INCLUDES DIFF/PLT)				
WHITE BLOOD CELL COUNT	4.1	NORMAL	3.8-10.8 Thousand/uL	01
RED BLOOD CELL COUNT	5.03	NORMAL	4.20-5.80 Million/uL	01
HEMOGLOBIN	14.9	NORMAL	13.2-17.1 g/dL	01
HEMATOCRIT	44.2	NORMAL	38.5-50.0 %	01
MCV	87.9	NORMAL	80.0-100.0 fL	01
MCH	29.6	NORMAL	27.0-33.0 pg	01
MCHC	33.7	NORMAL	32.0-36.0 g/dL	01
RDW	12.9	NORMAL	11.0-15.0 %	01
PLATELET COUNT	164	NORMAL	140-400 Thousand/uL	01
MPV	11.5	NORMAL	7.5-12.5 fL	01
ABSOLUTE NEUTROPHILS	2120	NORMAL	1500-7800 cells/uL	01
ABSOLUTE BAND NEUTROPHILS	DNR	NORMAL	0-750 cells/uL	01
ABSOLUTE METAMYELOCYTES	DNR	NORMAL	0 cells/uL	01
ABSOLUTE MYELOCYTES	DNR	NORMAL	0 cells/uL	01
ABSOLUTE PROMYELOCYTES	DNR	NORMAL	0 cells/uL	01
ABSOLUTE LYMPHOCYTES	1517	NORMAL	850-3900 cells/uL	01
ABSOLUTE MONOCYTES	394	NORMAL	200-950 cells/uL	01
ABSOLUTE EOSINOPHILS	49	NORMAL	15-500 cells/uL	01
ABSOLUTE BASOPHILS	21	NORMAL	0-200 cells/uL	01
ABSOLUTE BLASTS	DNR	NORMAL	0 cells/uL	01
ABSOLUTE NUCLEATED RBC	DNR	NORMAL	0 cells/uL	01
NEUTROPHILS	51.7	NORMAL	%	01
BAND NEUTROPHILS	DNR	NORMAL	%	01
METAMYELOCYTES	DNR	NORMAL	%	01
MYELOCYTES	DNR	NORMAL	%	01
PROMYELOCYTES	DNR	NORMAL	%	01
LYMPHOCYTES	37.0	NORMAL	%	01
REACTIVE LYMPHOCYTES	DNR	NORMAL	0-10 %	01
MONOCYTES	9.6	NORMAL	%	01
EOSINOPHILS	1.2	NORMAL	%	01
BASOPHILS	0.5	NORMAL	%	01
BLASTS	DNR	NORMAL	%	01
NUCLEATED RBC	DNR	NORMAL	0 /100 WBC	01
COMMENT(S)	DNR	NORMAL		01
HS CRP				
HS CRP	<0.2	NORMAL	mg/L	01

Verified by repeat analysis.

Lower relative cardiovascular risk according to AHA/CDC guidelines.

## For ages >17 Years:

hs-CRP mg/L Risk According to AHA/CDC Guidelines <1.0 Lower relative cardiovascular risk.

1.0-3.0 Average relative cardiovascular risk.

3.1-10.0 Higher relative cardiovascular risk.

Consider retesting in 1 to 2 weeks to exclude a benign transient elevation in the baseline CRP value secondary to infection or inflammation.

>10.0 Persistent elevation, upon retesting, may be associated with infection and inflammation.

#### HOMOCYSTEINE

HOMOCYSTEINE 4.2 NORMAL <11.4 umol/L 01
Homocysteine is increased by functional deficiency of
folate or vitamin B12. Testing for methylmalonic acid
differentiates between these deficiencies. Other causes
of increased homocysteine include renal failure, folate
antagonists such as methotrexate and phenytoin, and
exposure to nitrous oxide.

# DHEA SULFATE

DHEA SULFATE	91	LOW	106-464  mcg/dL	01
FERRITIN				
FERRITIN	586	HIGH	20-345 ng/mL	01
INSULIN				
INSULIN	2.3	NORMAL	2.0-19.6 uIU/mL	01
This insulin a	ssay shows strong cross-read	ctivity for		
some insulin a	nalogs (lispro, aspart, and	glargine)		

PROGESTERONE

glulisine).

INCOLDILITORE				
PROGESTERONE	<0.5	NORMAL	<1.4 ng/mL	01
TSH				
TSH	0.73	NORMAL	0.40-4.50 mIU/L	01
ESTRADIOL				
ESTRADIOL	30	NORMAL	< OR = 39 pg/mL	01

Reference range established on post-pubertal patient population. No pre-pubertal reference range established using this assay. For any patients for whom low Estradiol levels are anticipated (e.g. males, pre-pubertal children and hypogonadal/post-menopausal females), the Quest Diagnostics Nichols Institute Estradiol, Ultrasensitive, LCMSMS assay is recommended (order code 30289).

and much lower cross-reactivity with others (detemir,

Please note: patients being treated with the drug fulvestrant (Faslodex(R)) have demonstrated significant interference in immunoassay methods for estradiol measurement. The cross reactivity could lead to falsely elevated estradiol test results leading to an inappropriate clinical assessment of estrogen status. Quest Diagnostics order code 30289-Estradiol, Ultrasensitive LC/MS/MS demonstrates negligible cross reactivity with fulvestrant.

### VITAMIN D, 25-OH, TOTAL, IA

VITAMIN D, 25-OH, TOTAL, IA 41 NORMAL 30-100 ng/mL 01

Vitamin D Status 25-OH Vitamin D:

Deficiency: <20 ng/mL

Insufficiency: 20 - 29 ng/mL
Optimal: > or = 30 ng/mL

For 25-OH Vitamin D testing on patients on D2-supplementation and patients for whom quantitation of D2 and D3 fractions is required, the QuestAssureD(TM) 25-OH VIT D, (D2,D3), LC/MS/MS is recommended: order code 92888 (patients >2yrs).

For more information on this test, go to: http://education.questdiagnostics.com/faq/FAQ163 (This link is being provided for informational/educational purposes only.)

#### HEMOGLOBIN A1c WITH eAG

HEMOGLOBIN A1c 4.9 NORMAL <5.7 % of total Hgb 01

For the purpose of screening for the presence of diabetes:

<5.7% Consistent with the absence of diabetes 5.7-6.4% Consistent with increased risk for diabetes (prediabetes)

> or =6.5% Consistent with diabetes

This assay result is consistent with a decreased risk of diabetes.

Currently, no consensus exists regarding use of hemoglobin Alc for diagnosis of diabetes in children.

According to American Diabetes Association (ADA) guidelines, hemoglobin A1c <7.0% represents optimal control in non-pregnant diabetic patients. Different metrics may apply to specific patient populations. Standards of Medical Care in Diabetes(ADA).

eAG (mg/dL)	94	NORMAL	(calc)	01
eAG (mmol/L)	5.2	NORMAL	(calc)	01
TESTOSTERONE, FREE (DIALYSIS) A	AND TOTAL, MS			
TESTOSTERONE, TOTAL, MS	915	NORMAL	250-1100 ng/dL	02
TESTOSTERONE, FREE	101.8	NORMAL	35.0-155.0 pg/mL	02

\*\*Data from J Clin Invest 1974:53:819-828 and J Clin Endocrinol Metab 1973;36:1132-1142. Men with clinically significant hypogonadal symptoms and testosterone values repeatedly in the range of the 200-300 ng/dL or less, may benefit from testosterone treatment after adequate risk and benefits counseling.

For additional information, please refer to http://education.questdiagnostics.com/faq/FAQ165 (This link is being provided for informational/ educational purposes only.)

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute Valencia. It has not been cleared or approved by the US Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

## Performing Laboratory Information:

01: Quest Diagnostics-Lenexa, 10101 Renner Blvd, Lenexa KS, phone: , Medical Director: William J Becker

02: Quest Diagnostics-Nichols Valencia, 27027 Tourney Rd, Valencia CA, phone: , Medical Director: MD, PhD Jon Nakamoto